Serum proteomic-based analysis identifying autoantibodies against PRDX2 and PRDX3 as potential diagnostic biomarkers in nasopharyngeal carcinoma

Lie-Hao Lin1,2†, Yi-Wei Xu1,3†, Li-Sheng Huang4†, Chao-Qun Hong5, Tian-Tian Zhai4, Lian-Di Liao3,6, Wen-Jie Lin2, Li-Yan Xu3,6, Kai Zhang7, En-Min Li3,8‡ and Yu-Hui Peng1,3*‡

Abstract

Background: Nasopharyngeal carcinoma (NPC) is a major head and neck cancer with high occurrence in Southeast Asia and southern China. We aimed to identify autoantibodies that may contribute to early detection of NPC.

Methods: We used serological proteome analysis to identify candidate autoantibodies against tumor-associated antigens. Levels of autoantibodies and Epstein–Barr virus capsid antigen-IgA (VCA-IgA) were measured by ELISA in 129 patients with NPC and 100 normal controls. We employed receiver operating characteristics to calculate diagnostic accuracy.

Results: Sera from patients with NPC yielded multiple spots, two of which were identified as PRDX2 and PRDX3. Levels of serum autoantibodies against PRDX2 and PRDX3 were significantly higher for patients with NPC than for normal controls (P < 0.01), respectively. Combined detection of autoantibodies against PRDX2 and PRDX3 and VCA-IgA provided a high diagnostic accuracy in NPC (an area under the curve (AUC) of 0.811 (95% CI 0.753–0.869), 66.7% sensitivity, and 95.0% specificity). This combination maintained diagnostic performance for early NPC with AUC value of 0.754 (95% CI 0.652–0.857), 50.0% sensitivity, and 95.0% specificity.

Conclusions: This study reports autoantibodies against PRDX2 and PRDX3 identified by a proteomic approach in sera from NPC patients. Our findings suggest that autoantibodies against PRDX2 and PRDX3 may serve as supplementary biomarkers to VCA-IgA for the screening and diagnosis of NPC.

Keywords: Serological proteome analysis, Autoantibody, Peroxiredoxin, Early diagnosis, Nasopharyngeal carcinoma

Background

Nasopharyngeal carcinoma (NPC) is one of the most common tumors in the head and neck, with over 86,500 new cases in 2012 worldwide [1]. The geographical distribution of NPC is very unique, with 71% of all new cases in east, southeast Asia and the remainder in south-central Asia, and north and east Africa [1]. Besides difference in geographical condition, some ethnic groups including the Nagas in northern India, the Bidayuh in Borneo, and Inuits in the Artic, also appear to have a predisposition for NPC [2]. In the aspect of the demographics, men are two to three times more likely to suffer from NPC than are women, and peak incidence is between the ages of 50 and 60 years [1]. The overall survival in early-stage NPC patients is obviously longer than that in patients with advanced stage [3–5]. The 5 years’ survival rate for stage IVA, B and C patients were only 67, 68 and 18%, respectively, while it could reach up to 100 and 95% for stage
I and II patients after treatment, respectively [5]. Moreover, treatment-related morbidities more frequently occur in those patients with advanced disease [3]. However, due to deep anatomical site and the lack of specific symptoms at early stage, 75–90% of patients with NPC present with late stage of disease at clinical diagnosis [3, 6]. Thus, early diagnosis based on biomarker screening method may contribute significantly to NPC therapy and prognosis.

NPC is closely associated with Epstein–Barr virus (EBV), which is present in almost every NPC case, regardless of geographic distribution and histologic differentiation [7–9]. At present, the attempts for early NPC diagnosis mainly depends on various EBV-derived/related factors. EBV viral capsid antigen immunoglobulin A (VCA-IgA) and EBV DNA, the most commonly used serum/plasma biomarkers for NPC, have been found to be not sensitive and specific enough for early diagnosis purpose [10–12]. A recent meta-analysis showed that the sensitivity and specificity of VCA-IgA in diagnosis of NPC were 83 and 85%, respectively, and they were 75 and 87% for EBV DNA [12]. Other effective biomarkers for improving early NPC detection are thus clearly needed. In recent years, autoantibodies against tumor-associated antigens (TAAs) as serum biomarkers show potential availability for early cancer diagnosis, which could be detected prior to the onset of cancer [13–19]. Our previous studies also indicated that autoantibodies could serve as possible biomarkers for early detection of NPC [13, 14]. Here, we used a proteomic-based approach and identified novel TAAs PRDX2 and PRDX3 that induces an antibody response in patients with NPC.

**Methods**

**Study design and participants**

Approval for the study from the institutional ethics review committee center was obtained, and written informed consents were obtained from all patients and normal controls.

We included 7 NPC samples and 7 control samples in the “discovery” stage of this study (i.e. the serological proteome analysis, SERPA), who were consecutively collected from the Cancer Hospital of Shantou University Medical College, China, in February 2015. To further validate our findings in the SERPA, we performed the enzyme-linked immunosorbent assay (ELISA) in the validation stage using 129 NPC patients and 100 normal controls, which were recruited consecutively in the Cancer Hospital of SUMC from July, 2014, to July, 2015 and from the healthy staff members of this hospital between April, 2012, and June, 2014, respectively. Details for blood sample collection, processing and storage of serum sample of all participants were described in our previous publication [13].

**Cell line**

Human NPC cell line CNE2, obtained from Sun Yat-sen University Cancer Center, was cultured in RPMI-1640 medium plus 10% fetal bovine serum. All cells were incubated at 37 °C under an atmosphere of 5% CO₂.

**Two-dimensional polyacrylamide gel electrophoresis and Western blotting**

To discover novel autoantibodies in NPC patients, we followed the approach as described previously [21]. Protein extracts from cultured cells were diluted with two-dimensional gel electrophoresis (2-DE) sample buffer (8 M urea, 4.0% CHAPS, 0.2% (w/v) Ampholyte, 65 mM
Digests were extracted and concentrated to complete dryness using the SpeedVac and stored at −20 °C.

**In-gel digestion and purification of peptides**

Bands were excised from the gels and subjected to in-gel trypptic digestion. Briefly, the silver staining bands were excised and washed with 10% acetic acid/50% ethanol for overnight, and further soaked in water for 20 min. The gel slices were cut into 1 × 1 mm pieces after destained with 100 mM potassium ferricyanide and 30 mM sodium thiosulfate. The gel slabs were washed with water, 25 mM ammonium bicarbonate in ethanol/water and acetonitrile, respectively. After completely dehydrated, it was dried using the SpeedVac. Each sample was further subjected to reduction and alkylation as following procedure. DTT (final concentration of 5 mM) was added into the sample (final concentration of 0.1% (v/v) formic acid in water and injected into a Nano-LC system (EASY-nLC 1000, Thermo Fisher Scientific, Waltham, MA). The peptides were separated by a C18 column (50 μm inner-diameter × 15 cm) with a 60 min HPLC-gradient (linear gradient from 2 to 35% HPLC buffer B (0.1% formic acid in acetonitrile) in 50 min, and then to 90% buffer B in 10 min). The HPLC elution was electrospayed directly into a Q Exactive mass spectrometer (Thermo Fisher Scientific, Waltham, MA). The mass spectrometric analysis was carried out in a data-dependent mode, and the parameters were set as followings. The voltage at source was 1.8 kV. For full MS, scan range was from 350 to 1750 with the resolution of 70,000. The 10 most intense peaks with charge state 2 or 3 were selected for MS2 analysis (higher-energy collision dissociation: normalized collision energy of 27%, the resolution of MS2: 17,500 resolution, the dynamic exclusion duration for the data-dependant scan: 18 s, the repeat count: 2, and the exclusion window: ±1.5 Da). All MS/MS spectra were searched against the Uniprot-Human protein sequence database using the PD search engine (version 2.1.0, Thermo Fisher Scientific) with an overall false discovery rate (FDR) for peptides of less than 1%. Trypsin was specified as digesting enzyme. A maximum of 2 missing cleavages was allowed. Mass tolerances for precursor ions were set at ±10 ppm for precursor ions and ±0.02 Da for MS/MS. Oxidation of methionine and acetylation on protein N-terminal were fixed as variable modifications. Carbamidomethylation on Cys was specified as fixed modification. All MS/MS spectra were manually verified.

**ELISA for autoantibodies**

ELISA for autoantibodies against PRDX2 and PRDX3 was performed by two researchers (Yi-Wei Xu and Lie-Hao Lin) as previously described [13, 18]. Briefly, purified recombinant antigens, PRDX2 (Sino Biological Inc.) and PRDX3 (Abcam, ab168006) were diluted to a final protein concentration of 0.1 and 0.3 μg/ml, respectively. 100 μl of serum samples and quality control samples (i.e. a pooled serum sample collected randomly from 50 patients with NPC) were diluted (1/110), added to the plates, as well as appropriate control rabbit polyclonal antibodies specific for capture proteins (rabbit anti-PRDX2 polyclonal antibody, Sino Biological Inc; rabbit anti-PRDX3 polyclonal antibody, Sino Biological Inc). Horseradish peroxidase (HRP)-conjugated goat anti-human/rabbit IgG (Santa Cruz Biotechnology) was added at 1:10,000 dilution.

Quality control for monitoring of the ELISA assay was conducted according to our previous study [13, 18].

**ELISA for EBV VCA-IgA**

Concentrations of VCA-IgA in all samples were determined in duplicate by ELISA using commercial kits (Berer Bioengineering, Beijing, China). We conducted
the experiments according to the manufacturer’s instructions as previously described [13, 14].

Statistical analysis
We used the Mann–Whitney U test for analyses that compared levels of individual autoantibodies in serum between NPC patients and normal controls. For diagnostic ability of individual autoantibodies and jointly biomarker, we plotted receiver operating characteristic (ROC) analysis to assess optimum cutoff value, area under the ROC curve (AUC) with 95% confidence interval (CI), sensitivity, and specificity. The optimum cutoff value for positive reactivity was determined by achieving the maximum sensitivity when the specificity was >95%, and by minimizing the distance of the cutoff value to the top-left corner of the ROC curve. To test the diagnostic accuracy when the different markers were combined, we estimated functions of the combined markers by binary logistic regression, and the values of these functions were used as one marker and subjected to ROC analysis [22]. We used Chi-squared tests or Fisher’s exact tests for comparisons of the clinical relevance of individual and combined tests. All statistical analyses were performed with SPSS (version 17.0), or GraphPad Prism software. We considered a p value (two sided) of lower than 0.05 to be statistically significant.

Results
Identification of autoantibodies by serological proteome analysis
Human NPC CNE2 cell proteins were separated by 2-DE, and transferred onto PVDF membranes or visualized by silver staining (Fig. 1d). The membranes were screened individually from 7 NPC patients and from 7 matched normal controls to identify the presence of autoantibodies against candidate antigens from CNE2 cells. We selected 14 reactive spots in total observed in NPC patients for identification using the Nano-HPLC–MS/MS (Fig. 1a, b). Meanwhile there were no such reactive spots (or spots with weak immunoreactivity) within 7 healthy controls (Fig. 1c). We also observed that each selected target identified by the Nano-HPLC–MS/MS analysis correlated highly to the predicted molecular mass on gel from which it was originally excised (Table 2). Among these reactive spots, spot numbers 1 and 2, which were observed in 2 and 3 of 7 NPC patients, respectively (Fig. 1a), were identified as PRDX2 and PRDX3, respectively (Table 2). Both of the autoantibody biomarkers were selected to evaluate the diagnostic value for NPC with use of a validation cohort.

Validation of autoantibodies against PRDX2 and PRDX3 for NPC
In the validation stage, the circulating levels of autoantibodies against PRDX2 and PRDX3 on ELISA were significantly higher in NPC cases, respectively, compared with control individuals (Fig. 2, P < 0.01). ROC curve showed that the cutoff values of autoantibody against PRDX2 and PRDX3 were 0.173 and 0.608, respectively, with sensitivities/specificities of 26.4/96.0, 24.5/95.0%, and AUC values of 0.614 (95% CI 0.542–0.686) and 0.600 (95% CI 0.528–0.673) for discriminating NPC from normal controls (Fig. 3, Table 3). Predictive values and likelihood ratios for autoantibodies against PRDX2 and PRDX3 in the diagnosis of NPC are also shown in Table 3.

To estimate the diagnostic ability of the combined use of the two autoantibody markers, a variable predicted probability (p) of being detected as NPC was created based on an equation obtained by binary logistic regression (all NPC vs. all controls): ln (p/(1 − p)) = 6.040 × (PRDX2) + 2.062 × (PRDX3) − 1.339. The efficacy of combination of autoantibodies against PRDX2 and PRDX3 is presented in Fig. 3 and Table 3. Use of the combination of autoantibodies against PRDX2 and PRDX3 provided a sensitivity of 36.4% and a specificity of 95.0%.

Combined detection of autoantibodies and VCA-IgA for NPC
According to the manufacturer’s instructions, the recommended clinical cutoff value of VCA-IgA was 0.150. The sensitivities/specificities of VCA-IgA for all NPC and early-stage NPC were 48.8/95.0 and 32.5/95.0%, respectively (Table 3). We then examined whether the combined detection of VCA-IgA and autoantibody biomarkers would further improve the diagnostic accuracy for NPC. The predicted probability for NPC using the combination of two autoantibodies and VCA-IgA was calculated by: ln (p/(1 − p)) = 6.909 × (PRDX2) +2.757 × (PRDX3) + 3.107 × (VCA-IgA) − 2.414. As expected, ROC analysis illustrated that measurement of both autoantibody and VCA-IgA increased the diagnostic accuracy for NPC and early-stage NPC, compared with the test of the autoantibody or VCA-IgA alone (Fig. 4; Table 3).

The correlation of autoantibody assay positivity with Clinicopathological parameters
We evaluated the correlation of positive rates of the autoantibody assay with clinical variables in NPC patients. We did not find a correlation of assay positivity with any of the clinicopathological parameters of NPC patients (Table 4).
**Table 2** List of tumor proteins detected by proteomic identification

| Spot no. | Proteins                                      | Accession no. | Molecular weight (kDa) | Mascot score | Sequence coverage (%) |
|----------|-----------------------------------------------|---------------|------------------------|--------------|-----------------------|
| 1        | PRDX2                                         | P32119        | 21.9                   | 45.25        | 27.27                 |
| 2        | PRDX3                                         | P30048-2      | 25.8                   | 61.26        | 26.05                 |
| 3        | Nucleoside diphosphate kinase A               | P15531        | 17.1                   | 319.20       | 50.66                 |
| 4        | ENO1                                          | P06733        | 47.1                   | 1101.89      | 63.36                 |
| 5        | HSPA8                                         | P11142        | 70.9                   | 166.27       | 31.42                 |
| 6        | Serine-threonine kinase receptor-associated protein | Q9Y3F4     | 38.4                   | 149.54       | 32.86                 |
| 7        | HSPD1                                         | P10809        | 61.0                   | 724.87       | 38.57                 |
| 8        | Serpin B5                                      | P36952        | 42.1                   | 115.84       | 19.47                 |
| 9        | L-lactate dehydrogenase B                     | P07195        | 36.6                   | 428.81       | 35.93                 |
| 10       | Gamma-glutamylcyclotransferase                | Q75223        | 21.0                   | 40.35        | 20.74                 |
| 11       | Vimentin                                       | P08670        | 53.6                   | 177.94       | 45.06                 |
| 12       | NPM1                                           | P06748-2      | 29.4                   | 233.66       | 22.64                 |
| 13       | Isoform 2 of Macrophage-capping protein       | P40121-2      | 36.8                   | 47.09        | 10.21                 |
| 14       | Annexin A2                                     | P07355        | 38.6                   | 208.50       | 59.59                 |
Discussion

In this study, we found novel TAAs in NPC cell lines (CNE2) and related autoantibodies in serum of patients with NPC using SERPA. We then identified autoantibodies against PRDX2 and PRDX3 and verified their diagnostic values in 129 patients with NPC and 100 normal controls. Importantly, combined testing of the two autoantibody biomarkers and VCA-IgA in serum could provide improved result for diagnosing NPC.

The present study identified 14 tumor autoantibodies that might serve as potential biomarkers for NPC. To our knowledge, we first showed the four proteins, Serine-threonine kinase receptor-associated protein, Gamma-glutamylcyclotransferase, Serpin B5 and PRDX3, could induce autoantibodies among cancer patients. Using a validation cohort, we demonstrated that two of these biomarkers (autoantibodies against PRDX2 and PRDX3) represent novel autoantibody targets for discriminating NPC from normal controls. Interestingly, both of PRDX2 and PRDX3 identified are members of the Peroxiredoxin (PRDX) gene family [23]. Peroxiredoxins are a family of antioxidant enzymes, which are ubiquitously expressed and regulate levels of intracellular H₂O₂ by catalyzing reduction to water [24]. This highly conserved PRDX family participates in cellular antioxidant defense, and is also associated with cell signaling pathways involving cell proliferation, differentiation, apoptosis, and DNA damage [25, 26]. Several reports have mentioned

![Fig. 2](image1.png)

**Fig. 2** Levels of autoantibodies against PRDX2 and PRDX3. Scatter plots of OD values of autoantibodies against PRDX2 and PRDX3 from NPC sera and normal sera. Black horizontal lines are means.

![Fig. 3](image2.png)

**Fig. 3** ROC curve analysis of autoantibodies against PRDX2 and PRDX3 for NPC diagnosis. **a** ROC curve for serum autoantibodies against PRDX2 and PRDX3 and their combination for patients with NPC versus normal controls. **b** ROC curve for serum autoantibodies against PRDX2 and PRDX3 and their combination for patients with early NPC versus normal controls. ROC receiver operating characteristic.
PRDXs as tumor-associated antigen inducing autoantibody production in malignant tumor [13, 18, 27–29]. Ren et al. [27] demonstrated that positivity of autoantibody against PRDX1 was observed in sera from 9 of 68 (13.2%) patients with esophagus squamous cell carcinoma (ESCC), whereas no such activity was detected in 89 (0%) normal individuals. We previously showed that autoantibody against PRDX6 could serve as a potential serum biomarker for early detection of NPC and esophageal cancer [13, 18]. The present study was the first to show the presence of autoantibodies against PRDX2 and PRDX3 in sera from patients with NPC. We provided evidence that autoantibody against PRDX2 and PRDX3 could detected early-stage NPC (Table 3), showing their potential utility in early diagnosis of NPC.

The detection of cancer at early stage would contribute to the treatment and prognosis of cancer patients. There are evidences that the screening programs for the early detection of tumors, such as colorectal, prostate, breast, and lung cancer, can reduce mortality [30–32]. Although EBV DNA and antibodies against EBV antigens (e.g. VCA-IgA) are clinically used for NPC for many years, they may be of limited use as general screening test for NPC due to low specificity for distinguishing NPC from

### Table 3 Measurement of PRDX autoantibody, PRDX3 autoantibody and their combination of VCA-IgA in NPC diagnosis

|                         | AUC (95% CI) | Sensitivity (%) | Specificity (%) | PPV (%) | NPV (%) | PLR  | NLR  |
|-------------------------|-------------|----------------|-----------------|---------|---------|------|------|
| NPC versus NC           |             |                |                 |         |         |      |      |
| PRDX2 autoantibody      | 0.614 (0.542–0.686) | 26.4            | 96.0            | 89.5    | 50.3    | 6.60 | 0.77 |
| PRDX3 autoantibody      | 0.600 (0.528–0.673) | 24.5            | 95.0            | 86.3    | 49.4    | 4.90 | 0.79 |
| PRDX2 autoantibody + PRDX3 autoantibody | 0.632 (0.561–0.703) | 36.4            | 95.0            | 90.4    | 53.7    | 7.28 | 0.67 |
| VCA-IgA                 | 0.719 (0.653–0.785) | 48.8            | 95.0            | 92.6    | 59.0    | 9.76 | 0.54 |
| Autoantibody + VCA-IgA  | 0.811 (0.753–0.869) | 66.7            | 95.0            | 94.5    | 68.9    | 13.34| 0.35 |
| Early-stage NPC versus NC |         |                |                 |         |         |      |      |
| PRDX2 autoantibody      | 0.642 (0.532–0.753) | 27.5            | 96.0            | 73.4    | 76.8    | 6.88 | 0.76 |
| PRDX3 autoantibody      | 0.646 (0.537–0.755) | 25.0            | 95.0            | 66.7    | 76.0    | 5.00 | 0.79 |
| PRDX2 autoantibody + PRDX3 autoantibody | 0.664 (0.550–0.779) | 40.0            | 95.0            | 76.2    | 79.8    | 8.00 | 0.63 |
| VCA-IgA                 | 0.638 (0.528–0.747) | 32.5            | 95.0            | 72.3    | 77.8    | 6.50 | 0.71 |
| Autoantibody + VCA-IgA  | 0.754 (0.652–0.857) | 50.0            | 95.0            | 80.0    | 82.6    | 10.00| 0.53 |

AUC area under curve, 95% CI 95% exact confidence interval, NPC nasopharyngeal carcinoma, NC normal controls, PPV positive predictive value, NPV negative predictive value, PLR positive likelihood ratio, NLR negative likelihood ratio

**Fig. 4** ROC curve analysis of the combination of autoantibodies against PRDX2 and PRDX3, and VCA-IgA. 
- **a** ROC curve for the combination of autoantibodies against PRDX2 and PRDX3, and VCA-IgA for patients with NPC versus normal controls.
- **b** ROC curve for the combination of autoantibodies against PRDX2 and PRDX3, and VCA-IgA for patients with early NPC versus normal controls. ROC receiver operating characteristic; NPC.
other EBV-related diseases in endemic regions and high false positive rate for primary screening [33–35]. A reliable biomarker-based assay as a supplement to EBV DNA/VCA-IgA for the early NPC diagnosis is highly desirable. In recent years, autoantibodies show promising value of clinical application in terms of the early detection of cancer [13–19, 36–38]. For example, EarlyCDT-Lung, as a potential complementary tool to computed tomography, was the first autoantibody-based diagnostic biomarker to be performed for the early detection of lung cancer in routine clinical practice [36–38]. For a screening tool to be useful, the sensitivity and specificity would be as high as possible. However, to qualify as a clinically useful marker/ marker panel for initial detection of tumor disease, a molecular tumor marker/marker panel must have better diagnostic performance (i.e. sensitivity and specificity) than tumor markers currently used. We here measured the combination of autoantibodies against PRDX2 and PRDX3 and VCA-IgA in early-stage NPC and normal controls resulting in 50.0% sensitivity with a robust specificity of 95.0% (Table 3). The combined assay comprising VCA-IgA and autoantibodies against PRDX2 and PRDX3 demonstrated a better diagnostic ability than each one tested alone. Thus, the addition of autoantibodies, one kind of simple and cost-effective biomarkers, may improve the diagnostic efficacy for NPC. The high specificity suggests that this combined detection might also be used in assay positive patients to monitor therapy response or alternatively as a tool to detect recurrence. On the other hand, the sensitivity of this test would be not high enough to be used for screening purposes in general or high risk populations. Thus, we need to identify new autoantibody markers [e.g. other potential autoantibody markers identified in the present study (shown in Table 2)] that could enhance the sensitivity of our present combined assay.

Conclusions
To the best of our knowledge, we are the first to identify autoantibodies against PRDX2 and PRDX3 by a proteomic approach in sera from NPC patients. Our results

| Gender   | PRDX2 autoantibody | PRDX3 autoantibody | Combination |
|----------|--------------------|--------------------|-------------|
|          | Positive (%) | $\chi^2$ | $P$ | Positive (%) | $\chi^2$ | $P$ | Positive (%) | $\chi^2$ | $P$ |
| Male     | 100 | 26 (26.0%) | 1.564 | 0.211 | 25 (25.0%) | 0.099 | 0.925 | 34 (34.0%) | 1.138 | 0.286 |
| Female   | 29  | 11 (37.9%) | 7 (24.1%) | 16 (26.2%) | 0.126 | 0.723 | 13 (44.8%) | 1.00 | 0.312 |

| Age | PRDX2 autoantibody | PRDX3 autoantibody | Combination |
|-----|--------------------|--------------------|-------------|
| ≤50 | 61  | 19 (31.1%) | 0.344 | 0.558 | 16 (26.2%) | 0.126 | 0.723 | 21 (34.4%) | 0.201 | 0.654 |
| >50 | 68  | 18 (26.5%) | 16 (23.5%) | 16 (23.5%) | 0.126 | 0.723 | 26 (38.2%) | 0.213 | 0.612 |

| T stage | PRDX2 autoantibody | PRDX3 autoantibody | Combination |
|---------|--------------------|--------------------|-------------|
| T1 + T2 | 65  | 16 (24.6%) | 1.059 | 0.303 | 19 (29.2%) | 1.375 | 0.241 | 27 (41.5%) | 1.264 | 0.263 |
| T3 + T4 | 64  | 21 (32.8%) | 13 (20.3%) | 13 (20.3%) | 0.126 | 0.723 | 20 (31.3%) | 0.236 | 0.636 |

| N stage | PRDX2 autoantibody | PRDX3 autoantibody | Combination |
|---------|--------------------|--------------------|-------------|
| N0 + N1 | 67  | 20 (29.9%) | 0.093 | 0.760 | 15 (22.4%) | 0.437 | 0.509 | 25 (37.3%) | 0.408 | 0.524 |
| N2 + N3 | 62  | 17 (27.4%) | 17 (27.4%) | 17 (27.4%) | 17 (27.4%) | 0.126 | 0.723 | 22 (35.5%) | 0.437 | 0.509 |

| M stage | PRDX2 autoantibody | PRDX3 autoantibody | Combination |
|---------|--------------------|--------------------|-------------|
| M0      | 122 | 34 (27.9%) | 0.408 | 0.701 | 30 (24.6%) | 1.00 | 0.312 | 44 (36.1%) | 0.705 | 0.312 |
| M1      | 7   | 3 (42.9%) | 2 (28.6%) | 2 (28.6%) | 0.126 | 0.723 | 3 (42.9%) | 0.126 | 0.723 |

| Overall stage | PRDX2 autoantibody | PRDX3 autoantibody | Combination |
|---------------|--------------------|--------------------|-------------|
| I + II (early stage) | 40 | 11 (27.5%) | 0.040 | 0.842 | 10 (25.0%) | 0.001 | 0.973 | 16 (40.0%) | 0.318 | 0.573 |
| III + IV (advanced stage) | 89 | 26 (29.2%) | 22 (24.7%) | 22 (24.7%) | 0.040 | 0.842 | 31 (34.8%) | 0.705 | 0.312 |

**NPC nasopharyngeal carcinoma**

Statistical significance was determined by means of Chi-squared test or Fisher’s exact test (*)
reveal that autoantibodies against PRDX2 and PRDX3 might serve as a potential supplement to VCA-IgA in NPC diagnosis. The combined detection of VCA-IgA and autoantibodies against PRDX2 and PRDX3 had a better diagnostic sensitivity than VCA-IgA tested alone (Table 3; Fig. 4) and a robust specificity, indicating that this test might make a contribution to the diagnosis and screening of NPC patients. However, due to the small size of patients with early disease in the present study, we need to further address the early diagnostic value of this test in a large cohort study. Another limitation is that we just included 7 NPC patients with advanced disease in the discovery work. We would conduct comparative analysis of NPC Stage I/II versus Stage III/IV versus control to discover early autoantibody biomarkers in the future work. What’s more, our observations also suggest that we should conduct further study to validate the diagnostic ability of other autoantibodies identified in this study. We hope to establish and validate an optimized autoantibody panel with VCA-IgA in larger, blinded patient cohorts obtained from multiple institutions, which could have clinical and economical implications for NPC screening.

**Abbreviations**
- AUC: area under the ROC curve
- CI: confidence interval
- ELISA: enzyme-linked immunosorbent assay
- EBV: Epstein–Barr virus
- HRP: horseradish peroxidase
- NC: normal controls
- NPC: nasopharyngeal carcinoma
- NLR: negative likelihood ratio
- NPV: negative predictive value
- PLR: positive likelihood ratio
- PPV: positive predictive value
- ROC: receiver operating characteristic
- SERPA: serological proteome analysis
- TAA: tumor-associated antigen
- 2-DE: two-dimensional gel electrophoresis
- VCA-IgA: viral capsid antigen immunoglobulin A

**Authors’ contributions**
LHL and YWX performed all experimental work, data analysis and drafted the manuscript. LSH collected the patient samples, analyzed, interpreted the patient data and drafted the manuscript. TZT collected and analyzed the patient data. CQH and LDL conducted the experiments of cell culture. KZ provided technical input on the mass-spectrometry. EML, LYX and WJL contributed to the overall study design, data analysis and manuscript writing. All authors have read and approved the final manuscript.

**Author details**
1. Department of Clinical Laboratory Medicine, The Cancer Hospital of Shantou University Medical College, No. 7, Raoping Road, Shantou 515041, Guangdong, China.
2. Department of Orthopaedics, The Nanao People’s Hospital, Shantou 515099, China.
3. The Key Laboratory of Molecular Biology for High Cancer Incidence Coastal Chaoshan Area, Shantou University Medical College, Shantou 515041, China.
4. Department of Radiation Oncology, The Cancer Hospital of Shantou University Medical College, Shantou 515041, China.
5. Department of Oncological Laboratory Research, The Cancer Hospital of Shantou University Medical College, Shantou 515041, China.
6. Institute of Oncological Pathology, Shantou University Medical College, Shantou 515041, China.
7. Tianjin Key Laboratory of Medical Epigenetics, Department of Biochemistry and Molecular Biology, School of Basic Medical Sciences, Tianjin Medical University, Tianjin 300070, China.
8. Department of Biochemistry and Molecular Biology, Shantou University Medical College, Shantou 515041, China.

**Competing interests**
The authors declare that they have no competing interests.

**Availability of data and materials**
The datasets used during the current study available from the corresponding author on reasonable request.

**Ethics approval and consent to participate**
The study was reviewed and approved by the Institutional Review Board of the Cancer Hospital of Shantou University Medical College. Written informed consent was obtained from all participants in this study.

**Funding**
This work was supported by funding from the Science and Technology Program of Guangdong (2016ZC0165), the Shantou University Medical College Clinical Research Enhancement Initiative (201428), the Innovative and Strong School Project of Guangdong (2015KQNCX044), the Natural Science Foundation of China (31600632, 81172264 and 81472613), and the Department of Education, Guangdong Government under the Top-tier University Development Scheme for Research and Control of Infectious Diseases.

**Received:** 8 November 2016 **Accepted:** 19 January 2017

**Published online:** 01 February 2017

**References**
1. Chua ML, Wee JT, Hui EP, Chan AT. Nasopharyngeal carcinoma. Lancet. 2016;387:1012–24.
2. Wee JT, Ha TC, Loong SL, Qian CN. Is nasopharyngeal cancer really a ‘Cantonese cancer’? Chin J Cancer. 2010;29:517–26.
3. Lee AW, Sze WM, Au JS, Leung SF, Leung TW, Chua DT, et al. Treatment results for nasopharyngeal carcinoma in the modern era: the Hong Kong experience. Int J Radiat Oncol Biol Phys. 2005;61:1107–16.
4. Chen Y, Sun Y, Liang SB, Zong JF, Li WF, Chen M, et al. Progress report of a randomized trial comparing long-term survival and late toxicity of concurrent chemoradiotherapy with adjuvant chemotherapy versus radiotherapy alone in patients with stage III to IVB nasopharyngeal carcinoma from endemic regions of China. Cancer. 2013;119:2230–8.
5. Yip TT, Ngan RK, Fong AH, Law SC. Application of circulating plasma/serum EBV DNA in the clinical management of nasopharyngeal carcinoma. Oral Oncol. 2014;50:27–38.
6. Adham M, Kurniawan AN, Muhtadi A, Roszin A, Hermani B, Gondhowardi S, et al. Nasopharyngeal carcinoma in Indonesia: epidemiology, incidence, signs and symptoms at presentation. Chin J Cancer. 2012;31:185–96.
7. Pathmanathan R, Prasad U, Chandrika G, Sadler R, Flynn K, Raab-Traub N. Undifferentiated, nonkeratinizing, and squamous cell carcinoma of the nasopharynx. Variants of Epstein–Barr virus-infected neoplasia. Am J Pathol. 1995;146:1355–62.
8. Nicholls JM, Agathanggelou A, Fung K, Zeng X, Niedobitek G. The association of squamous cell carcinomas of the nasopharynx with Epstein–Barr virus shows geographical variation reminiscent of Burkitt’s lymphoma. J Pathol. 1997;183:164–8.
9. Adham M, Greijer AE, Verkuilen SA, Juvana H, Fleig S, Rachmadi L, et al. Epstein–Barr virus DNA load in nasopharyngeal brushings and whole blood in nasopharyngeal carcinoma patients before and after treatment. Clin Cancer Res. 2013;19:2175–86.
10. Song C, Yang S. A meta-analysis on the EBV DNA and VCA-IgA in diagnosis of Nasopharyngeal Carcinoma. Pak J Med Sci. 2013;29:885–90.
11. Tsang RK, Vlantis AC, Ho RW, Tam JS, To KF, van Hasselt CA. Sensitivity and specificity of Epstein–Barr virus IGA titer in the diagnosis of nasopharyngeal carcinoma: a three-year institutional review. Head Neck. 2004;26:598–602.
12. Shao JY, Li YH, Gao HY, Wu QL, Cui NJ, Zhang L, et al. Comparison of plasma Epstein–Barr virus (EBV) DNA levels and serum EBV immunoglobulin A/virus capsid antigen antibody titers in patients with nasopharyngeal carcinoma. Cancer. 2004;100:1162–70.
13. Peng YH, Xu YW, Huang LS, Zhai TT, Dai LH, Qiu SQ, et al. Autoantibody signatures combined with Epstein–Barr virus capsid antigen-IgA as a biomarker panel for the detection of nasopharyngeal carcinoma. Cancer Prev Res (Phila). 2015;8:729–36.
14. Peng YH, Xu YW, Qiu SQ, Hong CQ, Zhai TT, Li EM, et al. Combination of autoantibodies against NY-ESO-1 and viral capsid antigen immunoglobulin A for improved detection of nasopharyngeal carcinoma. Oncol Lett. 2014;8:1096–102.

15. Pedersen JW, Gentry-Maharaj A, Nastald A, Fournaka EQ, Dzamay A, Burnett M, et al. Cancer-associated autoantibodies to MUC1 and MUC4—a blinded case-control study of colorectal cancer in UK collaborative trial of ovarian cancer screening. Int J Cancer. 2014;134:2180–8.

16. Evans RL, Pottalla JF, Egland KA. Classifying patients for breast cancer by detection of autoantibodies against a panel of conformation-carrying antigens. Cancer Prev Res (Phila). 2014;7:545–55.

17. Qiu J, Choi G, Li L, Wang H, Pitteri SJ, Pereira-Faca SR, et al. Occurrence of autoantibodies to annexin I, 14-3-3 theta and LAMR1 in prediagnostic lung cancer sera. J Clin Oncol. 2008;26:5060–6.

18. Xu YW, Peng YH, Chen B, Wu ZY, Wu JY, Shen JH, et al. Autoantibodies as potential biomarkers for the early detection of esophageal squamous cell carcinoma. Am J Gastroenterol. 2014;109:36–45.

19. Peng YH, Xu YW, Guo H, Huang LS, Tan HZ, Hong CQ, et al. Combined detection of serum Dickkopf-1 and its autoantibodies to diagnose esophageal squamous cell carcinoma. Cancer Med. 2016;5:1388–96.

20. Chen L, Mao YP, Xie FY, Liu LZ, Sun Y, Tian L, et al. The seventh edition of the UICC/AJCC staging system for nasopharyngeal carcinoma is prognostically useful for patients treated with intensity-modulated radiotherapy from an endemic area in China. Radiother Oncol. 2012;104:331–7.

21. Fujita Y, Nakahishi T, Hiramatsu M, Mabuchi H, Miyamoto Y, Miyamoto A, et al. Proteomics-based approach identifying autoantibody against peroxiredoxin VI as a novel serum marker in esophageal squamous cell carcinoma. Clin Cancer Res. 2006;12:6415–20.

22. Shen Q, Fan J, Yang XR, Tan Y, Zhao W, Xu Y, et al. Serum DKK1 as a protein biomarker for the diagnosis of hepatocellular carcinoma: a large-scale, multicentre study. Lancet Oncol. 2012;13:817–26.

23. Wood ZA, Schröder E, Robin Harris J, Poole LB. Structure, mechanism and regulation of peroxiredoxins. Trends Biochem Sci. 2003;28:32–40.

24. Wood ZA, Poole LB, Karplus PA. Peroxiredoxin evolution and the regulation of hydrogen peroxide signaling. Science. 2003;300:650–3.

25. Butterfield LH, Merino A, Golub SH, Jewell W, Pingleton WW, Robertson JF. Audit of the autoantibody test, EarlyCDT-Lung: an immunobiomarker test as an aid to early detection of lung cancer. Cancer Prev Res (Phila). 2011;4:1126–34.

26. Chapman CJ, Healey GF, Maddison P, Peek L, Murray A, et al. EarlyCDT-Lung: an immunobiomarker test as an aid to early detection of lung cancer. Cancer Prev Res (Phila). 2013;6:1319–26.

27. Jett JR, Peek LJ, Fredericks L, Jewell W, Pingleton WW, Robertson JF. Audit of the autoantibody test, EarlyCDT-Lung, in 1600 patients: an evaluation of its performance in routine clinical practice. Lung Cancer. 2014;83:51–5.

28. Ummane R, Duscharla D, Baret C, Venz S, Schlommm T, Heinzer H, et al. Prostate cancer-associated autoantibodies in serum against tumor-associated antigens as potential new biomarkers. J Proteom. 2015;119:218–29.

29. Lacombe J, Mangé A, Bougnoux AC, Prassas I, Solassol J. A multiparametric serum marker panel as a complementary test to mammography for the diagnosis of node-negative early-stage breast cancer and DCIS in young women. Cancer Epidemiol Biomark Prev. 2014;23:1834–42.

30. Hitomi R,Urban N, Ramsey S, McIntosh M, Schwartz S, Reid B, et al. The case for early detection. Nat Rev Cancer. 2003;3:243–52.

31. Smith CA, Kakkinides V, Eyre H. American Cancer Society guidelines for the early detection of cancer. CA Cancer J Clin. 2005;56:11–26.

32. Rennert G. Prevention and early detection of colorectal cancer—new horizons. Recent Results Cancer Res. 2007;174:179–87.

33. Kutok JL, Wang F. Spectrum of Epstein–Barr virus-associated diseases. Annu Rev Pathol. 2006;1:375–404.

34. Chang KP, Hao SP, Chang JH, Wu CC, Tsang NM, Lee YS, et al. Macrophage inflammatory protein-Salpha is a novel serum marker for nasopharyngeal carcinoma detection and prediction of treatment outcomes. Clin Cancer Res. 2008;14:6979–87.

35. Henle G, Henle W. Epstein–Barr virus-specific IgA serum antibodies as an outstanding feature of nasopharyngeal carcinoma. Int J Cancer. 1976;17:1–7.

36. Lam S, Boyle P, Healey GF, Maddison P, Peek L, Murray A, et al. EarlyCDT-Lung: an immunobiomarker test as an aid to early detection of lung cancer. Cancer Prev Res (Phila). 2011;4:1126–34.

37. Chapman CJ, Healey GF, Murray A, Boyle P, Robertson C, Peck LJ, et al. EarlyCDT-Lung test: improved clinical utility through additional autoantibody assays. Tumor Biol. 2012;33:1319–26.

38. Jett JR, Peek LJ, Fredericks L, Jewell W, Pingleton WW, Robertson JF. Audit of the autoantibody test, EarlyCDT-Lung, in 1600 patients: an evaluation of its performance in routine clinical practice. Lung Cancer. 2014;83:51–5.

39. Anderson KS, LaBaer J. The sentinel within: exploiting the immune system for cancer biomarkers. J Proteome Res. 2005;4:1123–33.

40. Caron M, Choquet-Kastylevsky G, Joubert-Caron R. Cancer immunomics using autoantibody signatures for biomarker discovery. Mol Cell Proteom. 2007;6:1115–22.

41. Lu W, Fu Z, Wang H, Feng J, Wei J, Guo J. Peroxiredoxin 2 knockdown by RNA interference inhibits the growth of colorectal cancer cells by down-regulating Wnt/B-catenin signaling. Cancer Lett. 2014;343:190–9.

42. Ummane R, Barrette E, Venz S, Scharf C, Baret C, Manesssyer HA, et al. Peroxiredoxins 3 and 4 are overexpressed in prostate cancer tissue and affect the proliferation of prostate cancer cells in vitro. J Proteome Res. 2012;11:2452–66.